Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Deffered Revenue (2019 - 2025)

Immunocore Holdings' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 10.6% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $4.9 million, down 10.6%, while the annual FY2025 figure was $4.9 million, 10.6% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $4.9 million at Immunocore Holdings, down from $5.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $5.8 million in Q3 2024 and bottomed at $4.9 million in Q4 2025.
  • The 4-year median for Non-Current Deffered Revenue is $5.5 million (2024), against an average of $5.4 million.
  • The largest annual shift saw Non-Current Deffered Revenue increased 5.21% in 2023 before it fell 13.83% in 2025.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $5.2 million in 2022, then rose by 5.21% to $5.5 million in 2023, then dropped by 1.47% to $5.4 million in 2024, then dropped by 10.6% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Non-Current Deffered Revenue are $4.9 million (Q4 2025), $5.0 million (Q3 2025), and $5.2 million (Q2 2025).